Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5310087 | 0.89 | CYP1A2 (0.44) | MAPTPOLBKCNN3CLK4LMNA | |
| SCHEMBL5304358 | 0.87 | MAPT (0.45) | MAPTTP53POLBSMN1; SMN2CLK4 | |
| SCHEMBL5306369 | 0.85 | TP53 (0.48) | MAPTTP53POLBSMN1; SMN2GAA | |
| SCHEMBL5303639 | 0.82 | LMNA (0.44) | MAPTTP53POLBSMN1; SMN2LMNA | |
| SCHEMBL5306300 | 0.82 | MAPT (0.42) | MAPTPOLBSMN1; SMN2LMNA | |
| SCHEMBL5306913 | 0.81 | CDK2 (0.40) | MAPTPOLBGAA | |
| SCHEMBL5303482 | 0.81 | MAPT (0.47) | MAPTTP53POLBSMN1; SMN2KCNN3 | |
| SCHEMBL5306328 | 0.81 | F2 (0.47) | MAPTTP53SMN1; SMN2GAA | |
| SCHEMBL5311858 | 0.79 | LMNA (0.43) | MAPTPOLBKCNN3GAALMNA | |
| SCHEMBL5306559 | 0.79 | KDM4E (0.47) | MAPTTP53POLBGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007034279-A2 | C3A ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |